Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Healaflow in 27G Vitrectomy for RRD
NCT03542162Completed
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Jan 2017
- Primary completion
- Jul 2018
- Modality
- Injectable Hydrogels
01
Overview
Open-label, single-arm trial of Healaflow in rhegmatogenous retinal detachment (RRD), sponsored by Tianjin Medical University Eye Hospital. Primary endpoint: Postoperative Anatomic Outcome at 3 months. Started Jan 2017; status: completed.
02
Drugs
Healaflow
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on NCT03542162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542162.